Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Published online before print July 6, 2005, doi:10.1212/01.WNL.0000171745.13592.cb)
This Article
Right arrow Full Text (Rapid PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
01.WNL.0000171745.13592.cbv1
65/1/17    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Elkind, M. S.V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Elkind, M. S.V.
Received January 3, 2005
Accepted April 5, 2005

Implications of stroke prevention trials. Treatment of global risk

Mitchell S.V. Elkind MD, MS, FAAN*

From the Department of Neurology and Gertrude H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, and Columbia University Medical Center of New York-Presbyterian Hospital, New York, NY.


* To whom correspondence should be addressed. E-mail: mse13{at}columbia.edu.

Abstract-- Clinical trials have demonstrated that risk of cardiovascular events may be reduced in patients with stroke, using blood pressure (BP) reduction and statin therapy, independently of the presence of specific risk factors. These results suggest an alternative approach to secondary stroke prevention, focused more on global risk than on detection and modification of individual categorical risk factors such as hypertension, dyslipidemia, and diabetes mellitus. A risk-based approach is warranted because stroke patients are at high risk of several cardiovascular events, not just stroke, and because physiologic risk factors such as BP demonstrate a continuous, or log-linear, relationship with cardiovascular risk. Essential to the implementation of such an approach is the development of adequate risk stratification models for stroke patients. Based on limited available evidence, however, it appears that most patients who experience an ischemic stroke or TIA are at high long-term absolute risk of a subsequent cardiovascular event and should be treated with all available risk-reduction strategies.




This article has been cited by other articles:


Home page
StrokeHome page
R. L. Sacco
The 2006 William Feinberg Lecture: Shifting the Paradigm From Stroke to Global Vascular Risk Estimation
Stroke, June 1, 2007; 38(6): 1980 - 1987.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
M. S.V. Elkind and C. G. Benesch
Lowering cholesterol in patients with stroke: Raising the standard
Neurology, April 25, 2006; 66(8): 1140 - 1141.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2005 by AAN Enterprises, Inc.